EZH2 inhibitor treatment of non-small cell lung cancer cells bearing SMARCA4 mutations sensitizes these cells to chemotherapy, an effect that is not apparent in SMARCA4 wild-type cells (Fillmore et al. 2015). This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.